{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"47"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"150"}],"units":"Participants"}],"groups":[{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"BG000","title":"Arm 1 A Lead-In (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"BG001","title":"Arm 1 B (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"BG002","title":"Arm 2 A Lead-In (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"BG003","title":"Arm 2 B (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.\n\nAzacitidine: Given SC or IV\n\nVenetoclax: Given Orally\n\nNivolumab: Given IV","id":"BG004","title":"Arm 3 A Lead-In (Azacitidine, Nivolumab, Venetoclax)"},{"description":"Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.\n\nAzacitidine: Given SC or IV\n\nVenetoclax: Given Orally\n\nNivolumab: Given IV","id":"BG005","title":"Arm 3 B (Azacitidine, Nivolumab, Venetoclax)"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"54"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"96"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"45","upperLimit":"73","value":"60"},{"groupId":"BG001","lowerLimit":"22","upperLimit":"90","value":"71"},{"groupId":"BG002","lowerLimit":"25","upperLimit":"77","value":"66"},{"groupId":"BG003","lowerLimit":"21","upperLimit":"83","value":"66"},{"groupId":"BG004","lowerLimit":"48","upperLimit":"72","value":"67"},{"groupId":"BG006","lowerLimit":"21","upperLimit":"90","value":"69"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"3"},{"groupId":"BG006","value":"50"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"29"},{"groupId":"BG004","value":"3"},{"groupId":"BG006","value":"100"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG006","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG006","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG006","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"5"},{"groupId":"BG006","value":"127"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG006","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG006","value":"13"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"47"},{"groupId":"BG004","value":"6"},{"groupId":"BG006","value":"150"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"There were Zero participants enrolled on Arm 3 B due to no responses in the lead in phase."}